source
- Novartis' RNA drug del-brax hits primary endpoint in early-stage FSHD trialNovartis reported that its antisense oligonucleotide conjugate, del-brax, achieved the primary biomarker endpoint in a Phase 1/2 study of patients with facioscapulohumeral muscular dystrophy (FSHD)…
- Kardigan targets $320 million IPO to fund three late-stage heart drugsKardigan, a biotech focused on cardiovascular therapies, announced plans for an initial public offering that aims to raise about $320 million. The proceeds are intended to support the development…